Rapid testing methods are becoming increasingly vital for the accurate identification and treatment of diseases, including epidemic prevention. Selfdiagnostics Deutschland GmbH is revolutionizing this field of diagnostics with its innovative approaches and technologies.

Founded in Leipzig in 2011, the R&D company develops and manufactures products which can detect a variety of different illnesses. Their team of scientists and engineers created a platform of single-use multiplex molecular diagnostic tests for a range of infections, including COVID-19.

Medical problem-solving at this highest level requires a unique blend of know-how, infrastructure and funding. Leipzig proved itself to be an ideal location in this regard, offering the company numerous benefits:

• Situated at the center of Germany in the heart of Europe, making it a pivotal traffic and logistics hub (i.e. airport)
• Site of the life science hub BioCity with its customized laboratory, office, manufacturing and warehouse spaces
• Chance to collaborate with the best European universities, institutes and virology laboratories, e.g. the Fraunhofer Institute for Cell Therapy and Immunology
• Access to potential investors and additional funding, e.g. with the Sächsische Aufbaubank

The company established its headquarters on Leipzig’s BioCity Campus, which enables innovative Start Ups like Selfdiagnostics to mature into successful Grow Ups with wide market penetration.

Small as a credit card, the PCR testing platform combines the ease-of-use of a rapid test with the accuracy of a PCR test – with a fast turnaround. The COVID-19 Multitest e.g. delivers a reliable result with near 100% sensitivity and specificity in 45 minutes.